A correction – as long as it is not too severe – might not be a bad thing for the sector.
Medtechs rushed for the markets last year, but had an uneasy time once there.
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
IPOs of drug developers raised $9bn in the first half of 2021, a record amount that is hard to square with talk of moderation.
The first quarter of 2021 sets a new record, but the tide might be starting to turn.